Ra Capital Management, L.P. Sells 262,503 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ra Capital Management, L.P. sold 262,503 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $0.38, for a total value of $99,751.14. Following the transaction, the insider owned 361,229 shares in the company, valued at approximately $137,267.02. This represents a 42.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Wednesday, June 10th, Ra Capital Management, L.P. sold 45,923 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total value of $16,991.51.
• On Tuesday, June 9th, Ra Capital Management, L.P. sold 369,800 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total value of $136,826.00.
• On Tuesday, May 12th, Ra Capital Management, L.P. sold 101,151 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total value of $64,736.64.
• On Monday, May 11th, Ra Capital Management, L.P. sold 87,490 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.67, for a total value of $58,618.30.
• On Friday, May 8th, Ra Capital Management, L.P. sold 376,526 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.71, for a total transaction of $267,333.46.

Werewolf Therapeutics Stock Up 8.0%

NASDAQ:HOWL traded up $0.03 on Thursday, hitting $0.39. The stock had a trading volume of 805,388 shares, compared to its average volume of 538,108. The stock has a market cap of $19.16 million, a price-to-earnings ratio of -0.32 and a beta of 0.29. The company has a fifty day moving average price of $0.67 and a two-hundred day moving average price of $0.72. Werewolf Therapeutics, Inc. has a 1-year low of $0.36 and a 1-year high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.04. As a group, analysts anticipate that Werewolf Therapeutics, Inc. will post -1.08 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently issued reports on HOWL shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Monday, April 20th. Wall Street Zen downgraded shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Two analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Werewolf Therapeutics currently has a consensus rating of “Hold” and an average target price of $3.75.

Hedge Funds Weigh In On Werewolf Therapeutics

Several hedge funds have recently added to or reduced their stakes in HOWL. Regal Investment Advisors LLC increased its stake in Werewolf Therapeutics by 93.3% in the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock valued at $33,000 after purchasing an additional 25,389 shares during the last quarter. Vontobel Holding Ltd. grew its stake in Werewolf Therapeutics by 66.7% during the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after buying an additional 24,003 shares during the last quarter. Qube Research & Technologies Ltd purchased a new position in Werewolf Therapeutics during the 2nd quarter worth approximately $48,000. AQR Capital Management LLC purchased a new position in Werewolf Therapeutics during the 1st quarter worth approximately $79,000. Finally, Bridgeway Capital Management LLC grew its stake in Werewolf Therapeutics by 157.7% during the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after buying an additional 62,414 shares during the last quarter. 64.84% of the stock is currently owned by hedge funds and other institutional investors.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.